|
The following stocks are the leading risers and fallers on AIM on Friday. ---------- AIM - WINNERS ---------- Gelion PLC, up 13% at 21.50 pence, 12-month range 9.00p-30.00p. The London-based battery energy storage systems firm says its UK subsidiary OXLiD Ltd has secured £533,000 in government grant funding to advance its lithium-sulfur battery technology in collaboration with defence and aerospace firm QinetiQ PLC. The funding, awarded under the UK government’s Drive35 programme and facilitated by the Advanced Propulsion Centre UK, will support the scale-up and independent validation of Gelion’s proprietary sulfur cathode material in multi-layer pouch cells exceeding 10 amp-hours. The 12-month project has a total budget of around £1.1 million, with Gelion contributing primarily through expertise and technical resources. Gelion says the project will deliver demonstrators tested and validated by QinetiQ, providing third-party data to help de-risk adoption of lithium-sulfur batteries in defence, aerospace and automotive markets. Chief Executive Officer John Wood says the funding will allow Gelion to demonstrate ‘ultra-high energy density’ cells while meeting performance needs for strategic applications, adding that QinetiQ’s expertise in defence certification and cell manufacturing would support the pathway to commercialisation. ---------- AIM - LOSERS ---------- Futura Medical PLC, down 48% at 4.62p, 12-month range 4.00p-40.95p. The Guildford, Surrey-based sexual health products firm warns annual revenue will be ‘materially below expectations’, with a US patent milestone payment now set to fall in 2026. Adds that it is mulling a way to extend its cash runway and plans a ‘significant restructuring’. Cash and cash equivalents stood at £2.7 million at the end of August 2025, and this is expected to provide it with working capital until January. Futura adds: ‘In view of the reduced operating cash flow outlined above, the ongoing review of the business has been broadened to consider a range of potential options to create shareholder value including but not limited to alternative partnering/licensing and distribution arrangements for Eroxon alongside Eroxon Intense and WSD4000. This may include the sale of one or more assets of the business. The board continue to believe that there is value in the group’s assets and therefore development plans for both Eroxon Intense and WSD4000 continue to progress.’ Futura expects 2025 revenue between £1.3 million and £1.4 million, ‘materially below expectations’. It puts market expectations at £5 million. Sales of erectile dysfunction treatment Eroxon have been slower than originally anticipated. ‘Alongside this sales trend, under the terms of the company’s agreement with Haleon, a payment of $2.5 million is due upon the granting of a US patent for Eroxon that meets the contractual definition of a valid patent claim. All filings have been made and it had been anticipated that this milestone would be achieved in FY 2025, with the payment forming a portion of overall revenue in FY 2025 however it is now expected to crystalise in H1 2026,’ Futura adds. ---------- Thruvision Group PLC, down 20% at 1.37p, 12-month range 0.50p-18.00p. The Abingdon, England-based provider of walkthrough people-screening technology says pretax loss for the year that ended March 31 widens to £4.7 million from £2.9 million the year before, as revenue declines 46% to £4.2 million from £7.8 million. This reflects ‘a lack of any [orders]’ from its Materials division, compared to £3.4 million in sales a year earlier. ‘The significant reduction in revenue in the past financial year was a great disappointment. Although the sales pipeline contained numerous larger opportunities these were not brought to a successful conclusion in the period, a situation that we have addressed by making significant changes to our sales organisation and approach,’ says Executive Chair Tom Black. The company notes its weak performance ‘inevitably’ put pressure on its cash resources, which led to a fundraise in November and a strategic review in January, during which it considered a sale of the business. Thruvision in July this year said it has decided to remain independent and will carry out further capital raises. Black continues: ‘FY26 has started well and revenue at this point is well ahead of last year. Sales activity is also high although conversion of sales leads to revenue has slowed over the summer months. The increased focus on border security globally is being reflected in our pipeline, including renewed dialogue with US Customs & Border Protection. Retail Distribution is also very active and we have a number of exciting opportunities here too. As a result, the board believes it remains on track to achieve significant revenue growth this year.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
